When was Faeth Therapeutics founded?

Faeth Therapeutics was founded in 2019 and raised its 1st funding round 3 years after it was founded.

Where is Faeth Therapeutics located?

Faeth Therapeutics is headquartered in San Francisco, United States. It is registered at 237 Kearny Street #9245 San Francisco CA 94108.

Who is the current CEO of Faeth Therapeutics?

Anand Parikh of Faeth Therapeutics. They have also founded 1 company.

How many employees does Faeth Therapeutics have?

As of Jul 31, 2026, the latest employee count at Faeth Therapeutics is 37.

Is Faeth Therapeutics a funded company?

Faeth Therapeutics is a funded company, having raised a total of $92M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 18, 2022.

When was the latest funding round of Faeth Therapeutics?

Faeth Therapeutics' latest funding was a $***** Series A round on Aug 01, 2025, with participation from 9 investors.

Where does Faeth Therapeutics rank among its competitors?

Faeth Therapeutics ranks 499th amongst 3291 active competitors, of which 1119 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Faeth Therapeutics?

Faeth Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Faeth Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of personalized nutritional programs against cancer. The company offers the Faeth program, a precision cancer treatment that uses metabolism to starve cancer cells, depriving and providing resistance to standard treatments. The program includes meals, therapeutics, and on-demand support from Faeth nutritionists.

Website: www.faeththerapeutics.com/
Social
Email ID: *****@faeththerapeutics.com
Registered Address: 237 Kearny Street #9245 San Francisco CA 94108

Key Metrics

Founded Year

2019

Location

San Francisco, United States

Stage

Acquired

Total Funding

$92M in 3 rounds

Latest Funding Round

Series A, Aug 01, 2025, $*****

Investors

S2G Investments & 13 more

Ranked

499^th among 3291 active competitors

Employee Count

37 as on Jul 31, 2026

Similar Companies

Jazz Pharmaceuticals & 2983 more

Exit Details

Acquired by Sensei Biotherapeutics (Feb 18, 2026)

View Faeth Therapeutics' full profile

Faeth Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Faeth Therapeutics, Inc. CIN: 30-1195962 , United States, Active	Apr 08, 2019	-	9 (As on Dec 31, 2021)	-
FAETH THERAPEUTICS, INC CIN: 32090129878 , United States, Active	May 31, 2023	-	-	-

Faeth Therapeutics got acquired by Sensei Biotherapeutics on Feb 18, 2026.

Click here to take a look at Faeth Therapeutics's acquisition in detail

Faeth Therapeutics has raised a total funding of $92M over 3 rounds. Its first funding round was on Jan 18, 2022. Its latest funding round was a Series A round on Aug 01, 2025 for $*****. 9 investors participated in its latest round. Faeth Therapeutics has 14 institutional investors.

Here is the list of recent funding rounds of Faeth Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 01, 2025	1834787	Series A	8207367	2569155	6804873	2161824
Jun 30, 2022	4306929	Series A	6857903	2507871	3466757	Khosla Ventures & 5 more
Jan 18, 2022	8285956	Seed	2507794	8635371	Khosla Ventures & 1 more	Digitalis Ventures & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Faeth Therapeutics's funding rounds and investors

The founders of Faeth Therapeutics is Anand Parikh. Anand Parikh is the CEO of Faeth Therapeutics.

Here are the details of Faeth Therapeutics' key team members:

Anand Parikh: Founder & CEO of Faeth Therapeutics.
Contact Info: 1 email address

View details of Faeth Therapeutics's Founder profiles and Board Members

Faeth Therapeutics' employee count trend

Faeth Therapeutics has 37 employees as of Jul 26. Here is Faeth Therapeutics's employee count trend over the years:

Employee count trend for Faeth Therapeutics

Uncover Faeth Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Faeth Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Faeth Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
499th	Faeth Therapeutics 2019, San Francisco (United States), Acquired	Provider of personalized nutritional programs against cancer	$92M	Able Partners, iSelect Fund & 12 others	53/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Faeth Therapeutics's competitors? Click here to see the top ones

Faeth Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Faeth Therapeutics's sector:

Free

Oncology - Sector Report

Edition: July, 2026 (74 Pages)

View all reports related to Faeth Therapeutics

Media has covered Faeth Therapeutics for a total of 13 events in the last 1 year, 5 of them have been about company updates and 1 about people movement.